다른 서비스와 비교했을 때 0TDF 의 PE 비율은 어느 정도인가요?

0TDF은 Price-To-Earnings 비율(19x)을 기준으로 볼 때 동종 업계 평균(22.6x)과 비교했을 때 좋은 가치를 가지고 있습니다.

0TDF 의 PE 비율은 European Pharmaceuticals 업계의 다른 회사와 어떻게 비교됩니까?

0TDF 은 Price-To-Earnings 19 UK Pharmaceuticals 업계 평균( 31.4 x).

0TDF 의 PE 비율과 공정 PE 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PE 비율입니다.

0TDF 은 예상 19 Price-To-Earnings Price-To-Earnings ( 37 x).

미래 현금 흐름을 볼 때 0TDF 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

0TDF ( $35.55 )는 당사 추정치인 [[공정 가치]]( $101.87 )

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

Roche Holding (LSE:0TDF) - 주가, 뉴스 및 분석

0TDF 주식 개요

Roche Holding AG는 유럽, 북미, 라틴 아메리카, 아시아, 아프리카, 호주 및 오세아니아에서 제약 및 진단 사업을 영위하고 있습니다. 자세한 내용

0TDF 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	3/6
과거 실적	0/6
재무 상태	3/6
배당금	5/6

보상

공정 가치 추정치보다 낮은 65.1% 에서 거래

수익은 매년 11.15% 증가할 것으로 예상됩니다.

3.79% 의 안정적인 배당금을 지급합니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

부채비율이 높네요

재무 결과에 영향을 미치는 대규모 일회성 항목

Roche Holding AG 경쟁사

AstraZeneca

LSE:AZN

UK£162.4b

GSK

LSE:GSK

UK£54.9b

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

Novartis

SWX:NOVN

CHF 183.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Roche Holding
과거 주가
현재 주가	CHF 35.55
52주 최고치	CHF 41.85
52주 최저치	CHF 29.27
베타	0.15
11개월 변경	-12.40%
3개월 변경 사항	-15.05%
1년 변경 사항	5.49%
33년 변화	-27.20%
5년 변화	-6.89%
IPO 이후 변화	15.09%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	0TDF	GB Pharmaceuticals	GB 마켓
7D	0.4%	5.0%	2.2%
1Y	5.5%	2.5%	8.8%

수익률 대 산업: 0TDF 지난 1년 동안 2.5 %를 반환한 UK Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: 0TDF 지난 1년 동안 8.8 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 0TDF's price volatile compared to industry and market?
0TDF volatility
0TDF Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

안정적인 주가: 0TDF 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 0TDF 의 주간 변동성( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG는 유럽, 북미, 라틴 아메리카, 아시아, 아프리카, 호주 및 오세아니아에서 제약 및 진단 사업을 영위하고 있습니다. 빈혈, 혈액 및 고형 종양, 피부과, 혈우병, 염증 및 자가 면역, 신경계 질환, 안과, 호흡기 질환, 이식 등의 치료 분야에서 의약품을 공급하고 있습니다. 또한 다양한 치료 분야에 대한 제품을 개발하고 있습니다.

Roche Holding AG 기본 사항 요약

Roche Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요?
0TDF 기본 통계
시가총액	US$230.29b
수익(TTM)	US$11.98b
수익(TTM)	US$68.36b

19.0x

P/E 비율

3.3x

P/S 비율

0TDF 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
0TDF 손익 계산서(TTM)
수익	CHF 60.58b
수익 비용	CHF 15.43b
총 이익	CHF 45.16b
기타 비용	CHF 34.54b
수익	CHF 10.62b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	13.33
총 마진	74.54%
순이익 마진	17.53%
부채/자본 비율	104.8%

0TDF 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

3.8%

현재 배당 수익률

72%

지급 비율

0TDF 주식 개요

보상

위험 분석

Roche Holding AG 경쟁사

LSE:AZN

UK£162.4b

LSE:GSK

UK£54.9b

LSE:HIK

UK£4.4b

SWX:NOVN

CHF 183.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran